Festival of Biologics 2026 has ended. This guide stays up as the record of who was there. Next: Festival of Biologics 2027, Oct 5–7, 2027 in Basel
Antibody and protein engineering at Festival of Biologics 2026
Oct 13–15, 2026 Basel, Switzerland ~3k attendees Website
67 organizations at Festival of Biologics 2026 present work in antibody & protein engineering: 42 suppliers and service providers, 14 drug developers and 11 academic, government and non-profit bodies. Between them they bring 110 presentations to the program. Most represented: Novartis (29 on the program), Sanofi (9 on the program), AstraZeneca (6 on the program). As of Sep 26, 2026.
| Organization | Festival of Biologics 2026 Attendance |
|---|---|
Novartis Basel, Switzerland | |
Global pharmaceutical company whose contract manufacturing arm offers CDMO services for biologics, small molecules, cell and gene therapy, and fill-finish. | Booth Exhibiting at Booth 185 Keynote Tue Oct 13 09:10 Biotechnology, the Renaissance How advances in biology, AI and new treatment types are converging to change what medicine can do for patients. Chair Tue Oct 13 11:25 Chair Tue Oct 13 11:25 Chair Tue Oct 13 11:25 Talk Tue Oct 13 11:30 Panel Tue Oct 13 12:20 Chair Tue Oct 13 14:05 Talk Tue Oct 13 14:50 Intensified Upstream Processing: Fed‑Batch and Perfusion Options for Robust Scale-Up Ways to get more protein from cell cultures by feeding them steadily or continuously, and how to scale that up reliably. Talk Tue Oct 13 15:10 Panel Tue Oct 13 15:10 Panel Discussion: From Research to GMP: Making MSC Manufacturing Reproducible at Scale How to grow mesenchymal stromal cells, a kind of stem cell, the same way batch after batch as production scales up. Talk Tue Oct 13 15:30 Chair Tue Oct 13 16:45 Panel Tue Oct 13 17:30 Panel Discussion: Next Generation Antibody Formats Where antibody drug design is heading, from two-target antibodies and antibody-drug conjugates to AI's role in engineering them. Talk Tue Oct 13 17:30 What AI can do – or not – in Patient Engagement What AI can and cannot do when drug developers involve patients in research, and how to measure whether that involvement helps. Chair Wed Oct 14 11:25 Chair Wed Oct 14 11:25 Talk Wed Oct 14 12:10 Talk Wed Oct 14 12:30 Bovine AAV – a promising vector for pulmonary gene therapy Early results from using a cattle adeno-associated virus to deliver gene therapy to the lungs, including how immune systems recognise it. Talk Wed Oct 14 12:30 Chair Wed Oct 14 14:05 Talk Wed Oct 14 14:30 Commercial Considerations for CAR-T Therapy: Lessons Learned from Recent Blockbusters What makes CAR-T cancer therapies hard to sell worldwide, from complex manufacturing and shipping to getting treatment centres and payers ready. Talk Wed Oct 14 15:30 When the Target Moves: Building Robust DSP Through Science, Monitoring, and Learning Why purification steps that once worked can start failing when the material feeding them changes, and how monitoring catches that early. Chair Wed Oct 14 16:45 Chair Wed Oct 14 16:45 Talk Wed Oct 14 16:50 Talk Wed Oct 14 17:30 Protein Quality as a Critical Factor in Target Interference Assessment for Bioanalytical Assays How the quality of a lab-made protein can distort tests that check whether patients make antibodies against a biologic drug. Talk Wed Oct 14 17:50 An Oligonucleotide Program in Late-Stage Clinical Trials Lessons from keeping an anti-drug antibody test working for a cholesterol-lowering siRNA drug through late trials and a handover to a partner lab. Keynote Thu Oct 15 09:05 From Strategy to Delivery: Aligning Bioanalytical Innovation and Execution Across Clinical Phases How to decide what to measure, when and why, as biologic drugs move from early studies into late-stage clinical trials. Talk Thu Oct 15 09:40 Chair Thu Oct 15 11:15 Chair Thu Oct 15 11:15 |
Sanofi Paris, France | |
Talk Tue Oct 13 14:10 Talk Tue Oct 13 14:10 Talk Tue Oct 13 15:10 Talk Tue Oct 13 17:10 Talk Tue Oct 13 17:50 Talk Wed Oct 14 11:30 Talk Wed Oct 14 14:50 Breaking the Nanobody® half-life ceiling: pH-dependent Nanobody® molecules targeting a distinct FcRn epitope enable superior pharmacokinetics and broad therapeutic applications A small antibody fragment that binds a new site on the receptor controlling protein recycling, letting the drug last longer in the body. Talk Thu Oct 15 12:40 | |
AstraZeneca Cambridge, United Kingdom | |
Talk Tue Oct 13 16:50 Optimizing recombinant protein expression workflows by leveraging automation and predictive models Ways to speed up making proteins in the lab by combining automated workflows with models that predict the best genetic code choices. Talk Tue Oct 13 17:50 Advancing Antibody Discovery Through Integrated single B-Cell Technologies How to find therapeutic antibodies by profiling individual immune B cells, and how computer predictions are combined with the laboratory work. Talk Wed Oct 14 12:30 Chair Wed Oct 14 16:45 Talk Wed Oct 14 16:50 Integrating AI/ML into Biologics Discovery: Design, Optimization, Developability, and Immunogenicity How AI supports biologic drug discovery, from designing molecules to predicting how easily they are made and whether the body attacks them. Talk Thu Oct 15 12:20 Talk Thu Oct 15 12:20 |
Find buyers in antibody & protein engineering
Tell us what you sell and we’ll find the people at organizations working on antibody & protein engineering most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse Festival of Biologics 2026 by
- Antibody & protein engineering 67
- AI & computational design 38
- Bispecifics & multispecifics 13
- ADCs & armed antibodies 18
- Immunotherapy & oncology 44
- Cell & gene therapy 28
- Therapeutic vaccines 13
- Peptides & GLP-1 7
- Bioprocessing & manufacturing 87
- CMC, formulation & analytics 58
- Clinical development 45
- Regulation & market access 40
Not affiliated with or endorsed by the Festival of Biologics or its organizers. Submit a correction